Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer.


Journal

European urology focus
ISSN: 2405-4569
Titre abrégé: Eur Urol Focus
Pays: Netherlands
ID NLM: 101665661

Informations de publication

Date de publication:
03 2019
Historique:
received: 25 04 2017
revised: 15 08 2017
accepted: 21 09 2017
pubmed: 22 11 2017
medline: 18 12 2019
entrez: 22 11 2017
Statut: ppublish

Résumé

The oncological efficacy of routine lymphadenectomy (lymph node dissection [LND]) at the time of radical nephroureterectomy (RNU) remains controversial. To systematically review the available literature assessing the impact of LND in upper tract urothelial carcinoma (UTUC) patients. Embase, Medline, and Cochrane databases were searched for all studies comparing outcomes of patients undergoing RNU without LND versus any form of LND. We identified nine retrospective studies eligible for inclusion in this systematic review. We took cancer-specific survival (CSS) as the primary end point, and performed a narrative review and risk of bias assessment. Six studies compared outcomes of no LND versus LND. Three studies compared complete LND versus incomplete LND versus no LND. The incidence of pN+ in patients with high-stage (≥pT2) tumours ranged from 14.3% to 40%. Pre- and postoperative characteristics differed among the study groups, potentially biasing the results, as demonstrated by the risk of bias assessment, potentially favouring the LND group. Oncological outcomes such as cancer-specific, overall, recurrence-free, and metastasis-free survival were reviewed, demonstrating a survival benefit with LND in high-stage disease of the renal pelvis. Template-based and complete LND improves CSS in patients with high-stage (≥pT2) UTUC and reduces the risk of local recurrence. The impact of LND in ureteral tumours remains uncertain. Studies comparing radical nephroureterectomy with or without the removal of nodes (lymph node dissection [LND]) were analysed. LND improves survival in patients with high-stage disease of the renal pelvis, if it is performed according to an anatomical template-based approach.

Identifiants

pubmed: 29158169
pii: S2405-4569(17)30236-5
doi: 10.1016/j.euf.2017.09.015
pii:
doi:

Types de publication

Comparative Study Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

224-241

Informations de copyright

Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Jose Luis Dominguez-Escrig (JL)

Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain. Electronic address: jldominguez@fivo.org.

Benoit Peyronnet (B)

Department of Urology, University of Rennes, Rennes, France.

Thomas Seisen (T)

Academic Department of Urology, La Pitié-Salpétrière Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France.

Harman M Bruins (HM)

Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

Cathy Yuhong Yuan (CY)

Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, ON, Canada.

Marko Babjuk (M)

Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic.

Andreas Böhle (A)

Department of Urology, HELIOS Agnes-Karll-Krankenhaus, Bad Schwartau, Germany.

Maximilian Burger (M)

Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany.

Eva M Compérat (EM)

Department of Pathology, La Pitié-Salpétrière Hospital, UPMC, Paris, France.

Paolo Gontero (P)

A.O.U. San Giovanni Battista-le Molinette, Department of Urology, University of Turin, Turin, Italy.

Thomas Lam (T)

Academic Urology Unit, University of Aberdeen, Scotland, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, Scotland, UK.

Steven MacLennan (S)

Academic Urology Unit, University of Aberdeen, Scotland, UK.

Hugh Mostafid (H)

Department of Urology, North Hampshire Hospital, Basingstoke, UK.

Joan Palou (J)

Department of Urology, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, Spain.

Bas W G van Rhijn (BWG)

Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antonie van Leeuwenhoek Hospital, Amsterdam, The Netherlands.

Richard J Sylvester (RJ)

European Association of Urology Guidelines Office, Brussels, Belgium.

Richard Zigeuner (R)

Department of Urology, Medical University of Graz, Graz, Austria.

Shahrokh F Shariat (SF)

Medical University of Vienna, Vienna General Hospital, Vienna, Austria.

Morgan Rouprêt (M)

Academic Department of Urology, La Pitié-Salpétrière Hospital, Assistance-Publique Hôpitaux de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH